Despite the multi-billion dollar successes of conventional pharmacological interventions for Alzheimer's disease, lackluster treatment outcomes have revealed them to be an abject failure. The ongoing hypothesis for the past few decades has been that Alzheimer's disease is caused by a lack of the neurotransmitter acetylcholine, but acetycholinesterase inhibitors (drugs that inhibit the enzyme that breaks this neurotransmitter down) have failed miserably to produce anything but momentary palliative improvements, if that. In addition, post-marketing surveillance data now clearly shows these drugs may actually cause new, more serious neurological problems,such as seizures.
Source : >